Does the media favor RARE or TBPH?

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 5 mentions for Theravance Biopharma. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Theravance Biopharma's score of 0.31 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ultragenyx Pharmaceutical 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to IDYA or TBPH?

In the previous week, IDEAYA Biosciences had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 5 mentions for Theravance Biopharma. IDEAYA Biosciences' average media sentiment score of 0.49 beat Theravance Biopharma's score of 0.31 indicating that IDEAYA Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ARQT or TBPH?

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Theravance Biopharma. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 5 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.68 beat Theravance Biopharma's score of 0.31 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GMTX or TBPH?

Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 14.79%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Theravance Biopharma 0 Sell rating(s) 8 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor GMTX or TBPH?

In the previous week, Theravance Biopharma had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Theravance Biopharma and 1 mentions for Gemini Therapeutics. Theravance Biopharma's average media sentiment score of 0.31 beat Gemini Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TBPH or ADPT?

In the previous week, Adaptive Biotechnologies had 12 more articles in the media than Theravance Biopharma. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 5 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.31 beat Adaptive Biotechnologies' score of 0.15 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Theravance Biopharma (TBPH) Competitors

$16.90 -0.03 (-0.18%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$16.90 +0.01 (+0.03%)

As of 07/13/2026 06:18 PM Eastern

Compare

TBPH vs. RARE, IDYA, ARQT, GMTX, and ADPT

Should you buy Theravance Biopharma stock or one of its competitors? MarketBeat compares Theravance Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Theravance Biopharma include Ultragenyx Pharmaceutical (RARE), IDEAYA Biosciences (IDYA), Arcutis Biotherapeutics (ARQT), Gemini Therapeutics (GMTX), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

How does Theravance Biopharma compare to Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical (NASDAQ:RARE) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability.

In the previous week, Ultragenyx Pharmaceutical had 5 more articles in the media than Theravance Biopharma. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 5 mentions for Theravance Biopharma. Ultragenyx Pharmaceutical's average media sentiment score of 1.25 beat Theravance Biopharma's score of 0.31 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ultragenyx Pharmaceutical	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ultragenyx Pharmaceutical presently has a consensus price target of $58.41, indicating a potential upside of 75.83%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.79%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 5.2% of Ultragenyx Pharmaceutical shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ultragenyx Pharmaceutical has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Theravance Biopharma has a net margin of 104.34% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Theravance Biopharma's return on equity of 18.84% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%
Theravance Biopharma	104.34%	18.84%	10.94%

Theravance Biopharma has lower revenue, but higher earnings than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ultragenyx Pharmaceutical	$673M	4.86	-$575M	-$6.11	N/A
Theravance Biopharma	$107.46M	8.11	$105.89M	$2.20	7.68

Summary

Theravance Biopharma beats Ultragenyx Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Theravance Biopharma compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

Theravance Biopharma has a net margin of 104.34% compared to IDEAYA Biosciences' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Theravance Biopharma	104.34%	18.84%	10.94%

98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 4.7% of IDEAYA Biosciences shares are held by insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

IDEAYA Biosciences currently has a consensus target price of $50.25, indicating a potential upside of 39.00%. Theravance Biopharma has a consensus target price of $19.40, indicating a potential upside of 14.79%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, IDEAYA Biosciences had 4 more articles in the media than Theravance Biopharma. MarketBeat recorded 9 mentions for IDEAYA Biosciences and 5 mentions for Theravance Biopharma. IDEAYA Biosciences' average media sentiment score of 0.49 beat Theravance Biopharma's score of 0.31 indicating that IDEAYA Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Theravance Biopharma has lower revenue, but higher earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	14.52	-$113.70M	-$1.60	N/A
Theravance Biopharma	$107.46M	8.11	$105.89M	$2.20	7.68

IDEAYA Biosciences has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its stock price is 83% less volatile than the broader market.

Summary

Theravance Biopharma beats IDEAYA Biosciences on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, institutional ownership, profitability, media sentiment, risk and dividends.

Arcutis Biotherapeutics presently has a consensus price target of $34.00, indicating a potential upside of 25.37%. Theravance Biopharma has a consensus price target of $19.40, indicating a potential upside of 14.79%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	9.02	-$16.14M	-$0.03	N/A
Theravance Biopharma	$107.46M	8.11	$105.89M	$2.20	7.68

Theravance Biopharma has a net margin of 104.34% compared to Arcutis Biotherapeutics' net margin of -0.57%. Theravance Biopharma's return on equity of 18.84% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Theravance Biopharma	104.34%	18.84%	10.94%

99.1% of Theravance Biopharma shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Arcutis Biotherapeutics had 6 more articles in the media than Theravance Biopharma. MarketBeat recorded 11 mentions for Arcutis Biotherapeutics and 5 mentions for Theravance Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.68 beat Theravance Biopharma's score of 0.31 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcutis Biotherapeutics has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Summary

Arcutis Biotherapeutics beats Theravance Biopharma on 9 of the 16 factors compared between the two stocks.

How does Theravance Biopharma compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Theravance Biopharma (NASDAQ:TBPH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Theravance Biopharma has higher revenue and earnings than Gemini Therapeutics. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Theravance Biopharma	$107.46M	8.11	$105.89M	$2.20	7.68

In the previous week, Theravance Biopharma had 4 more articles in the media than Gemini Therapeutics. MarketBeat recorded 5 mentions for Theravance Biopharma and 1 mentions for Gemini Therapeutics. Theravance Biopharma's average media sentiment score of 0.31 beat Gemini Therapeutics' score of 0.00 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.17, meaning that its share price is 83% less volatile than the broader market.

75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 7.7% of Theravance Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Theravance Biopharma has a net margin of 104.34% compared to Gemini Therapeutics' net margin of 0.00%. Theravance Biopharma's return on equity of 18.84% beat Gemini Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Theravance Biopharma	104.34%	18.84%	10.94%

Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 14.79%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Theravance Biopharma beats Gemini Therapeutics on 13 of the 14 factors compared between the two stocks.

How does Theravance Biopharma compare to Adaptive Biotechnologies?

Theravance Biopharma (NASDAQ:TBPH) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

Theravance Biopharma currently has a consensus target price of $19.40, suggesting a potential upside of 14.79%. Adaptive Biotechnologies has a consensus target price of $20.83, suggesting a potential downside of 0.89%. Given Theravance Biopharma's higher probable upside, equities analysts plainly believe Theravance Biopharma is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Theravance Biopharma has a net margin of 104.34% compared to Adaptive Biotechnologies' net margin of -16.82%. Theravance Biopharma's return on equity of 18.84% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Theravance Biopharma has higher earnings, but lower revenue than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$107.46M	8.11	$105.89M	$2.20	7.68
Adaptive Biotechnologies	$276.98M	12.15	-$59.50M	-$0.33	N/A

Theravance Biopharma has a beta of 0.17, suggesting that its share price is 83% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.07, suggesting that its share price is 107% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 12 more articles in the media than Theravance Biopharma. MarketBeat recorded 17 mentions for Adaptive Biotechnologies and 5 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.31 beat Adaptive Biotechnologies' score of 0.15 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	5 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Theravance Biopharma beats Adaptive Biotechnologies on 9 of the 16 factors compared between the two stocks.

Get Theravance Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TBPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TBPH vs. The Competition

Export

Metric	Theravance Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$872.79M	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	7.68	19.17	27.11	24.26
Price / Sales	8.11	838.79	589.96	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	2.88	4.22	10.74	6.29
Net Income	$105.89M	$64.26M	$3.58B	$330.66M
7 Day Performance	-0.65%	-3.58%	-2.11%	-1.35%
1 Month Performance	1.56%	2.12%	3.27%	-0.64%
1 Year Performance	47.34%	20.35%	26.31%	19.08%

Theravance Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TBPH Theravance Biopharma	3.0214 of 5 stars	$16.90 -0.2%	$19.40 +14.8%	+49.6%	$872.79M	$107.46M	7.68	110
RARE Ultragenyx Pharmaceutical	3.6316 of 5 stars	$35.99 +6.8%	$59.56 +65.5%	+12.6%	$3.55B	$673M	N/A	1,371	Positive News
IDYA IDEAYA Biosciences	3.4862 of 5 stars	$39.84 +1.2%	$50.25 +26.1%	+60.8%	$3.50B	$218.71M	N/A	80
ARQT Arcutis Biotherapeutics	3.8875 of 5 stars	$27.00 +3.6%	$34.00 +25.9%	+80.7%	$3.35B	$376.07M	N/A	150	Analyst Upgrade
GMTX Gemini Therapeutics	N/A	$76.26 +1.7%	N/A	+34.6%	$3.30B	N/A	N/A	30	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TBPH) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Theravance Biopharma (TBPH) Competitors

TBPH vs. RARE, IDYA, ARQT, GMTX, and ADPT

How does Theravance Biopharma compare to Ultragenyx Pharmaceutical?

Summary

How does Theravance Biopharma compare to IDEAYA Biosciences?

Summary

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Summary

How does Theravance Biopharma compare to Gemini Therapeutics?

Summary

How does Theravance Biopharma compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Theravance Biopharma (TBPH) Competitors

TBPH vs. RARE, IDYA, ARQT, GMTX, and ADPT

How does Theravance Biopharma compare to Ultragenyx Pharmaceutical?

Does the media favor RARE or TBPH?

Do analysts recommend RARE or TBPH?

Do insiders & institutionals hold more shares of RARE or TBPH?

Which has more risk & volatility, RARE or TBPH?

Is RARE or TBPH more profitable?

Which has better valuation and earnings, RARE or TBPH?

Summary

How does Theravance Biopharma compare to IDEAYA Biosciences?

Is IDYA or TBPH more profitable?

Do insiders and institutionals hold more shares of IDYA or TBPH?

Do analysts recommend IDYA or TBPH?

Does the media refer more to IDYA or TBPH?

Which has higher earnings & valuation, IDYA or TBPH?

Which has more volatility & risk, IDYA or TBPH?

Summary

How does Theravance Biopharma compare to Arcutis Biotherapeutics?

Do analysts recommend ARQT or TBPH?

Which has preferable valuation & earnings, ARQT or TBPH?

Is ARQT or TBPH more profitable?

Do institutionals & insiders believe in ARQT or TBPH?

Does the media refer more to ARQT or TBPH?

Which has more volatility and risk, ARQT or TBPH?

Summary

How does Theravance Biopharma compare to Gemini Therapeutics?

Which has preferable valuation and earnings, GMTX or TBPH?

Does the media favor GMTX or TBPH?

Which has more risk and volatility, GMTX or TBPH?

Do institutionals & insiders hold more shares of GMTX or TBPH?

Is GMTX or TBPH more profitable?

Do analysts recommend GMTX or TBPH?

Summary

How does Theravance Biopharma compare to Adaptive Biotechnologies?

Do analysts rate TBPH or ADPT?

Is TBPH or ADPT more profitable?

Do insiders & institutionals hold more shares of TBPH or ADPT?

Which has better earnings and valuation, TBPH or ADPT?

Which has more volatility & risk, TBPH or ADPT?

Does the media refer more to TBPH or ADPT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TBPH vs. The Competition

Theravance Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools